Kalaris Therapeutics, Inc. (KLRS) - Total Liabilities
Based on the latest financial reports, Kalaris Therapeutics, Inc. (KLRS) has total liabilities worth $41.25 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Kalaris Therapeutics, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Kalaris Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See Kalaris Therapeutics, Inc. short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Kalaris Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Kalaris Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SinoMedia Holding Limited
F:SJY
|
Germany | €107.21 Million |
|
Orian Sh.M. Ltd
TA:ORIN
|
Israel | ILA390.57 Million |
|
CVC Income & Growth Limited
LSE:CVCE
|
UK | €316.00K |
|
Tait Marketing & Distribution Co Ltd
TWO:5902
|
Taiwan | NT$431.38 Million |
|
Climb Global Solutions
NASDAQ:CLMB
|
USA | $343.60 Million |
|
Wellspire Holdings Berhad
KLSE:0271
|
Malaysia | RM7.56 Million |
|
EcoFirst Consolidated Bhd
KLSE:3557
|
Malaysia | RM463.23 Million |
|
Pollux Investasi Internasional Tbk PT
JK:POLI
|
Indonesia | Rp2.14 Trillion |
Liability Composition Analysis (2018–2025)
This chart breaks down Kalaris Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Kalaris Therapeutics, Inc. market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.60 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.38 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kalaris Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kalaris Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Kalaris Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $42.92 Million | +719.28% |
| 2024-12-31 | $5.24 Million | -89.16% |
| 2023-12-31 | $48.35 Million | +41.49% |
| 2022-12-31 | $34.17 Million | -44.28% |
| 2021-12-31 | $61.33 Million | +245.37% |
| 2020-12-31 | $17.76 Million | -0.23% |
| 2019-12-31 | $17.80 Million | +376.26% |
| 2018-12-31 | $3.74 Million | -- |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudativ… Read more